
Optimata
Founded Year
1999Stage
Other Investors | AliveAbout Optimata
Optimata Ltd. is a privately-owned science-based interdisciplinary company engaged in biosimulation technology for optimizing drug treatment protocols. Optimata partners with pharmaceutical and biotechnology companies to develop effective new treatments for diseases by simulating disease processes. This aims to reduce time-to-market and development costs while improving the competitive profile of the newly developed drug.
Loading...
Loading...
Optimata Patents
Optimata has filed 7 patents.
The 3 most popular patent topics include:
- combination drugs
- genetics
- genomics

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/4/2015 | 10/12/2021 | Machine learning, Design of experiments, Medical terminology, Epidemiology, Health informatics | Grant |
Application Date | 3/4/2015 |
---|---|
Grant Date | 10/12/2021 |
Title | |
Related Topics | Machine learning, Design of experiments, Medical terminology, Epidemiology, Health informatics |
Status | Grant |
Optimata Frequently Asked Questions (FAQ)
When was Optimata founded?
Optimata was founded in 1999.
What is Optimata's latest funding round?
Optimata's latest funding round is Other Investors.
Who are the investors of Optimata?
Investors of Optimata include Brooks Keret Group and Trimaran Capital Partners.
Who are Optimata's competitors?
Competitors of Optimata include TheraVida, Flexion Therapeutics, Presage Biosciences, Foamix Pharmaceuticals, Curemark and 7 more.
Loading...
Compare Optimata to Competitors

Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).
Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.
The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution and Lyophilized injection, in areas like anesthialogy and oncology.
RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.
Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.
Loading...